BeiGene's zanubrutinib leads to 84% ORR in Chinese pivotal trial for MCL

BeiGene Ltd. (NASDAQ:BGNE) said zanubrutinib (BGB-3111) led to an overall response rate (ORR)

Read the full 134 word article

User Sign In